Provided by Tiger Trade Technology Pte. Ltd.

Exelixis

44.21
+1.082.50%
Post-market: 44.840.6300+1.43%19:43 EST
Volume:2.09M
Turnover:91.89M
Market Cap:11.85B
PE:18.60
High:44.44
Open:43.03
Low:42.96
Close:43.13
52wk High:49.62
52wk Low:31.90
Shares:268.11M
Float Shares:231.84M
Volume Ratio:0.71
T/O Rate:0.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.38
EPS(LYR):1.80
ROE:30.56%
ROA:17.73%
PB:5.49
PE(LYR):24.60

Loading ...

Exelixis’s Strategic Positioning and Market Prospects Justify Buy Rating Amid RCC Treatment Dynamics

TIPRANKS
·
Oct 28

Apple, MARA, Exelixis, Strategy, Dell: Trending by Analysts

TIPRANKS
·
Oct 25

Press Release: Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Dow Jones
·
Oct 22

Exelixis Shares Rise After Leerink Partners Upgrade

MT Newswires Live
·
Oct 22

Exelixis Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Oct 22

Exelixis Price Target Maintained With a $45.00/Share by RBC Capital

Dow Jones
·
Oct 21

Exelixis price target lowered to $44 from $50 at Morgan Stanley

TIPRANKS
·
Oct 21

Leerink Partners Upgrades Exelixis to Outperform From Market Perform, Adjusts Price Target to $48 From $38

MT Newswires Live
·
Oct 21

Synox Therapeutics Strengthens Board of Directors With Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress

THOMSON REUTERS
·
Oct 21

Exelixis Raised to Outperform From Market Perform by Leerink Partners

Dow Jones
·
Oct 21

US Equity Markets Close Higher Amid Gains in Tech Stocks, Falling Government Bond Yields

MT Newswires Live
·
Oct 21

Exelixis’s Zanzalintinib Shows Promise in Phase III Trial, Justifying Buy Rating Despite Safety Concerns

TIPRANKS
·
Oct 21

Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results

Benzinga_recent_news
·
Oct 20

Exelixis falls -12.5%

TIPRANKS
·
Oct 20

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Benzinga
·
Oct 20

S&P 500 Futures Climb In Premarket Trading; Exelixis, Summit Therapeutics Lag

Dow Jones
·
Oct 20

Exelixis Reports Detailed Results of Phase 3 Trial of Cancer Combo Treatment; Shares Down Pre-Bell

MT Newswires Live
·
Oct 20

Exelixis’s Zanza: A Strong Contender with Promising Survival Rates and Manageable Safety Profile

TIPRANKS
·
Oct 20

BRIEF-Exelixis announces detailed results from late-stage pivotal trial

Reuters
·
Oct 20

Exelixis reports detailed results from STELLAR-303

TIPRANKS
·
Oct 20